Fresh from the designation pipeline: orphan drugs recently designated in the European Union (November 2012 – January 2013)

Bibliography

• Antoniu S. Fresh from the designation pipeline: orphan drugs recently designated in the European Union. Exp Opin Orphan Drugs 2013;1(3):249-53
   Web of Science ®Google Scholar
• Turner MD, Chaudhry A, Nedjai B. Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 2012;32(2):105-12. Available from: www.ema.europa.eu
   Google Scholar
• Dhimolea E. Canakinumab. MAbs 2010;2(1):3-13. Available from: www.ema.europa.eu
   PubMed Web of Science ®Google Scholar
• European, M, Agency. Canakinumab for the treatment of tumour necrosis factor receptor-associated periodic syndrome. 2012
   Google Scholar
• Novartis Phase III study showed 62% of patients with most severe form of childhood arthritis were symptom-free with ACZ885 treatment. 2012. Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1617524.shtml
   Google Scholar
• Comenzo RL. How i treat amyloidosis. Blood 2009;114(15):3147-57. Available from: www.ema.europa.eu
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012;109(24):9629-34. Available from: www.ema.europa.eu
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79(8):785-92. Available from: www.ema.europa.eu
   PubMed Web of Science ®Google Scholar
• European, M, Agency. Tafamidis for treatment of senile systemic amyloidosis. 2012
   Google Scholar
• Rossmiller B, Mao H, Lewin AS. Gene therapy in animal models of autosomal dominant retinitis pigmentosa. Mol Vis 2012;18:2479-96. Available from: www.ema.europa.eu
   Google Scholar
• European, M, Agency. Adeno-associated viral vector encoding an inducible short hairpin RNA targeting claudin-5 (prior to administration of 17-dimethylaminoethylamino-17-demethocygeldanamycin) for the treatment of retinitis pigmentosa; 2012
   Google Scholar
• Lipinski DM, Singh MS, MacLaren RE. Assessment of cone survival in response to CNTF, GDNF, and VEGF165b in a novel ex vivo model of end-stage retinitis pigmentosa. Invest Ophthalmol Vis Sci 2011;52(10):7340-6. Available from: www.ema.europa.eu
   Google Scholar
• Kauper K, McGovern C, Sherman S, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci 2012;53(12):7484-91. Available from: www.ema.europa.eu
   PubMed Web of Science ®Google Scholar
• European, M, Agency. Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor for the treatment of retinitis pigmentosa. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/03/WC500139544.pdf
   Google Scholar
• Gourronc FA, Robertson MM, Herrig AK, et al. Proliferative defects in dyskeratosis congenita skin keratinocytes are corrected by expression of the telomerase reverse transcriptase, TERT, or by activation of endogenous telomerase through expression of papillomavirus E6/E7 or the telomerase RNA component, TERC. Exp Dermatol 2010;19(3):279-88. Available from: www.ema.europa.eu
   Google Scholar
• European, M, Agency. Public summary of opinion on orphan designation-Recombinant human dyskerin for the treatment of dyskeratosis congenita. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2012/12/WC500136191.pdf
   Google Scholar
• Newton KF, Mallinson EK, Bowen J, et al. Genotype-phenotype correlation in colorectal polyposis. Clin Genet 2012;81(6):521-31. Available from: www.ema.europa.eu
   Google Scholar
• Tonelli F, Valanzano R, Dolara P. Sulindac therapy of colorectal polyps in familial adenomatous polyposis. Dig Dis 1994;12(5):259-64. Available from: www.ema.europa.eu
   Google Scholar
• Mackenzie GG, Ouyang N, Xie G, et al. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res 2011;4(7):1052-60. Available from: www.ema.europa.eu
   Google Scholar
• European,M, Agency. Public summary of opinion on orphan designation-Eflornithine in combination with sulindac for the treatment of familial adenomatous polyposis; 2012
   Google Scholar
• Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. Am Fam Physician 2008;78(8):961-8. Available from: www.ema.europa.eu
   Google Scholar
• European, M, Agency. Tracleer (bosentan); 2002
   Google Scholar
• Antoniu SA. Terguride for pulmonary arterial hypertension. Expert Opin Ther Targets 2011;15(11):1333-5. Available from: www.ema.europa.eu
   PubMed Web of Science ®Google Scholar
• Kekewska A, Görnemann T, Jantschak F, et al. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells. J Pharmacol Exp Ther 2012;340(2):369-76. Available from: www.ema.europa.eu
   Google Scholar
• European,M, Agency. Terguride for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2007. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000308.jsp&mid=WC0b01ac058001d12b
   Google Scholar
• European, M, Agency. Public summary of opinion on orphan designation-Terguride for the treatment of systemic sclerosis. 2013
   Google Scholar
• European, M, Agency. Public summary of opinion on orphan designation-Terguride for the treatment of systemic sclerosis; 2013
   Google Scholar
• Van Den Berg-Vos RM, Van Den Berg LH, Visser J, et al. The spectrum of lower motor neuron syndromes. J Neurol 2003;250(11):1279-92
   Google Scholar
• Meyer K, Miranda CJ, Kaspar BK. Transplantation of gene-corrected motor neurons as a therapeutic strategy for spinal muscular atrophy. Mol Ther 2013;21(3):502-3
   Google Scholar
• European,M, Agency. Public summary of opinion on orphan designation-Allogeneic motor neuron progenitor cells derived from human embryonic stem cells for the treatment of 5q spinal muscular atrophy; 2013
   Google Scholar
• Richette P, Bardin T, Stheneur C. Achondroplasia: from genotype to phenotype. Joint Bone Spine 2008;75(2):125-30. Available from: www.ema.europa.eu
   Google Scholar
• Lorget F, Kaci N, Peng J, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet 2012;91(6):1108-14. Available from: www.ema.europa.eu
   PubMed Web of Science ®Google Scholar
• European, M, Agency. Public summary of opinion on orphan designation-Modified recombinant human C-type natriuretic peptide for the treatment of achondroplasia; 2013
   Google Scholar
• Valstar MJ, Bruggenwirth HT, Olmer R, et al. Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis 2010;33(6):759-67. Available from: www.ema.europa.eu
   PubMedGoogle Scholar
• Fu H, Dirosario J, Killedar S, et al. Correction of Neurological Disease of Mucopolysaccharidosis IIIB in Adult Mice by rAAV9 Trans-Blood-Brain Barrier Gene Delivery. Mol Ther 2011;19(6):1025-33. Available from: www.ema.europa.eu
   PubMed Web of Science ®Google Scholar
• European, M, Agency. Public summary of opinion on orphan designation-Adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase alpha gene for the treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome); 2013
   Google Scholar
• International Rare Disease Research Consortium. Available from: http://www.irdirc.org/
   Google Scholar
• Applied Clinical Research on Very Rare Diseases – call for proposals. Available from: http://www.nihr.ac.uk/research/Pages/VeryRareDiseasesResearch.aspx
   Google Scholar